2 completed, 1 terminated. 2 Phase 3, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
| Phase 4 | 1 | Completed 1 |
Follow Transderm Scop®: new trials by email Literature Review of Transderm Scop® trials Research Report on Transderm Scop®
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness DPI-386 Nasal Gel, Placebos - Motion Sickness | Phase 3 | Completed | Repurposed Therapeutics, Inc. | 102 | 2019-06-09 | 2019-12-03 |
| DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness DPI-386 Nasal Gel, DPI-386 Placebo Nasal Gel, Transderm Scop® - Motion Sickness | Phase 2 / Phase 3 | Terminated | Repurposed Therapeutics, Inc. | 23 | 2018-06-29 | 2020-01-07 |
| Scopolamine Patch Pharmacokinetics in Healthy Adults Transderm Scop®, Intravenous scopolamine hydrobromide - Healthy | Phase 4 | Completed | University of Iowa | 26 | 2016-11-01 | 2018-06-21 |
Motion Sickness (2)
Repurposed Therapeutics, Inc. (2) · University of Iowa (1)
United States (3)
David Helton (1) · David R Helton (1)